Literature DB >> 21559749

Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

Lucia Carulli1, Stefano Ballestri, Amedeo Lonardo, Francesca Lami, Enrico Violi, Luisa Losi, Lisa Bonilauri, Anna Maria Verrone, Maria Rosaria Odoardi, Federica Scaglioni, Marco Bertolotti, Paola Loria.   

Abstract

Hypothyroidism is associated with the risk of development of the metabolic syndrome (MS) and hypercholesterolemia. Direct evidence that hypothyroidism might be associated with advanced chronic liver disease via nonalcoholic steatohepatitis (NASH) is limited. We studied the relationship between thyroid hormones, thyroid stimulating hormone (TSH), cholesterol, and NASH. In consecutive euthyroid patients with biopsy-proven nonalcoholic fatty liver disease, TSH and thyroid hormone (FT3 and FT4) concentrations were compared in 25 patients with steatosis and 44 non-cirrhotic NASH patients featuring concurrent ballooning, lobular inflammation and steatosis. The MS was diagnosed according to ATP III criteria. A meta-analysis of previously published studies was performed to evaluate whether NASH, compared to simple steatosis, is associated with lower cholesterol levels. At univariate analysis, compared to those with steatosis, patients with NASH have a wider waist, elevated levels of BMI, ALT, AST, fasting insulin, HOMA-IR, ferritin, TSH and a lower serum cholesterol. At stepwise multivariable logistic regression analysis, the independent predictors of NASH are high HOMA and TSH and lower total cholesterol (Model 1); MS and high TSH (Model 2). At meta-analysis, serum total cholesterol levels are significantly lower in predominantly non-cirrhotic NASH than in simple steatosis. This study provides cross-sectional and meta-analytic evidence that, in euthyroid patients, high-though-normal TSH values are independently associated with NASH. Further work is needed to ascertain the role, if any, of lower cholesterol serum levels in assisting in the diagnosis of NASH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21559749     DOI: 10.1007/s11739-011-0609-4

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  42 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease.

Authors:  Mika Yamamoto; Motoh Iwasa; Kazuko Iwata; Masahiko Kaito; Ryosuke Sugimoto; Naohito Urawa; Rumi Mifuji; Masayoshi Konishi; Yoshinao Kobayashi; Yukihiko Adachi
Journal:  J Gastroenterol Hepatol       Date:  2007-04       Impact factor: 4.029

Review 3.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

Authors:  Camilo Boza; Arnoldo Riquelme; Luis Ibañez; Ignacio Duarte; Enrique Norero; Paola Viviani; Alejandro Soza; Jose Ignacio Fernandez; Alejandro Raddatz; Sergio Guzman; Marco Arrese
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

5.  Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins.

Authors:  Ian D Bookman; J Pham; M Guindi; E J Heathcote
Journal:  Liver Int       Date:  2006-06       Impact factor: 5.828

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis.

Authors:  M Nannipieri; F Cecchetti; M Anselmino; E Mancini; G Marchetti; A Bonotti; S Baldi; B Solito; M Giannetti; A Pinchera; F Santini; E Ferrannini
Journal:  Obes Surg       Date:  2008-10-16       Impact factor: 4.129

9.  Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery.

Authors:  Florence Harnois; Simon Msika; Jean-Marc Sabaté; Charlotte Mechler; Pauline Jouet; Jeanine Barge; Benoit Coffin
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

10.  Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India.

Authors:  Ghanshyam Palamaner Subash Shantha; Anita A Kumar; Vijay Jeyachandran; Deepan Rajamanickam; K Rajkumar; Shihas Salim; Kuyilan Karai Subramanian; Senthilkumar Natesan
Journal:  Thyroid Res       Date:  2009-03-09
View more
  30 in total

Review 1.  Physical activity for the prevention and treatment of metabolic disorders.

Authors:  Luca Montesi; Simona Moscatiello; Marcella Malavolti; Rebecca Marzocchi; Giulio Marchesini
Journal:  Intern Emerg Med       Date:  2013-05-09       Impact factor: 3.397

Review 2.  The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

Authors:  Christina C Lindenmeyer; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

3.  Thyroid Dysfunction and Nonalcoholic Fatty Liver Disease: We Need New Larger and Well-Designed Longitudinal Studies.

Authors:  Alessandro Mantovani; Giorgio Grani
Journal:  Dig Dis Sci       Date:  2018-04-19       Impact factor: 3.199

4.  Pharmacological agents for nonalcoholic steatohepatitis.

Authors:  Maeva Guillaume; Vlad Ratziu
Journal:  Hepatol Int       Date:  2013-11-19       Impact factor: 6.047

Review 5.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

6.  Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease.

Authors:  Ahmet Sert; Ozgur Pirgon; Ebru Aypar; Hakan Yilmaz; Dursun Odabas
Journal:  Pediatr Cardiol       Date:  2013-01-24       Impact factor: 1.655

7.  Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study.

Authors:  Kil Woo Lee; Ki Bae Bang; Eun Jung Rhee; Heon Ju Kwon; Mi Yeon Lee; Yong Kyun Cho
Journal:  Clin Mol Hepatol       Date:  2015-12-24

Review 8.  Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.

Authors:  Ahad Eshraghian; Alireza Hamidian Jahromi
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

9.  Hepatic steatosis and thyroid function tests in overweight and obese children.

Authors:  L Pacifico; E Bonci; F Ferraro; G Andreoli; S Bascetta; C Chiesa
Journal:  Int J Endocrinol       Date:  2013-02-03       Impact factor: 3.257

10.  High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes.

Authors:  Ying Tan; Xixiang Tang; Panwei Mu; Yi Yang; Mei Li; Yuanpeng Nie; Haicheng Li; Yanhua Zhu; Yanming Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-22       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.